(Q27851971)

English

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

scientific article

In more languages

Statements

scholarly article

1 reference

13 November 2016

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study (English)

1 reference

13 November 2016

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Pasi A Jänne

0 references

author name string

Alice T Shaw

2

0 references

José Rodrigues Pereira

3

0 references

Gaëlle Jeannin

4

0 references

Johan Vansteenkiste

5

0 references

Carlos Barrios

6

0 references

Fabio Andre Franke

7

0 references

Lynda Grinsted

8

0 references

Victoria Zazulina

9

0 references

Paul Smith

10

0 references

Ian Smith

11

0 references

Lucio Crinò

12

0 references

publication date

January 2013

0 references

Lancet Oncology Commission

0 references

14

0 references

38-47

0 references

1

0 references

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970489-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70489-8

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27851971&oldid=1980673000"